Industry Press

1/18/2011 – 01:45 PM

miRagen Therapeutics Named University of Colorado Technology Transfer Office Bioscience Company of the Year

01/18/2011 – 08:00 AM

Mirna Therapeutics and Collaborators Publish New Data on miR-34 and its Role in Cancer Stem Cells

01/12/2011 – 02:00 PM

Asuragen Announces New Notices of Allowance from USPTO Related to the Diagnostic Applications of Cancer-Related miRNAs at the JP Morgan Healthcare Conference

01/06/2011 – 07:30 AM

Alnylam Launches “Alnylam 5×15” Product Strategy and Provides Guidance and Goals for 2011

01/05/2011 – 12:30 PM

Research and Markets: Biochips – Technologies, Markets and Companies – Updated Report with Projected Value to 2015 and 2020

01/05/2011 – 08:30 AM

Regulus Therapeutics Promotes Garry E. Menzel, Ph.D., to Chief Operating Officer and Executive Vice President of Finance

01/04/2011 – 03:27 PM

Research and Markets: RNAi – An Updated Report on Technologies, Markets and Companies

01/04/2011 – 07:30 AM

Alnylam Demonstrates RNAi in Man with Systemically Delivered RNAi Therapeutics

Related posts:

1. Industry Press Update
2. Recent Industry Press
3. Recent microRNA Press
4. A Busy Month in the Business of microRNA
5. Global miRNA Market Outlook

Tagged as: Alnylum, asuragen, microrna, mirna, miRNA array, mirna therapeutics, Regulus